CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma

• Published in: Oncotarget Vol. 7; no. 45; pp. 73558 - 73572
• Main Authors: Mohanty, Atish, Sandoval, Natalie, Das, Manasi, Pillai, Raju, Chen, Lu, Chen, Robert W, Amin, Hesham M, Wang, Michael, Marcucci, Guido, Weisenburger, Dennis D, Rosen, Steven T, Pham, Lan V, Ngo, Vu N
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 08.11.2016
• Subjects: Antineoplastic Agents - pharmacology; Apoptosis - drug effects; Apoptosis - genetics; Cell Line, Tumor; Cell Survival - drug effects; Cell Survival - genetics; Cyclin D1 - genetics; Cyclin D1 - metabolism; Drug Resistance, Neoplasm - genetics; Humans; Lymphoma, Mantle-Cell - genetics; Lymphoma, Mantle-Cell - metabolism; Mutation; Phosphorylation; Protein Kinase Inhibitors - pharmacology; Protein Stability; Protein Transport; Proteolysis; Pyrazoles - pharmacology; Pyrimidines - pharmacology; Research Paper; Ubiquitination; ibrutinib resistance; somatic mutations; mantle cell lymphoma; cyclin D1
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.12434

Mantle cell lymphoma (MCL) is characterized by the t(11;14) translocation, which leads to deregulated expression of the cell cycle regulatory protein cyclin D1 (CCND1). Genomic studies of MCL have also identified recurrent mutations in the coding region of CCND1. However, the functional consequence of these mutations is not known. Here, we showed that, compared to wild type (WT), single E36K, Y44D or C47S CCND1 mutations increased CCND1 protein levels in MCL cell lines. Mechanistically, these mutations stabilized CCND1 protein through attenuation of threonine-286 phosphorylation, which is important for proteolysis through the ubiquitin-proteasome pathway. In addition, the mutant proteins preferentially localized to the nucleus. Interestingly, forced expression of WT or mutant CCND1 increased resistance of MCL cell lines to ibrutinib, an FDA-approved Bruton tyrosine kinase inhibitor for MCL treatment. The Y44D mutant sustained the resistance to ibrutinib even at supraphysiologic concentrations (5-10 μM). Furthermore, primary MCL tumors with CCND1 mutations also expressed stable CCND1 protein and were resistant to ibrutinib. These findings uncover a new mechanism that is critical for the regulation of CCND1 protein levels, and is directly relevant to primary ibrutinib resistance in MCL.